Weil, Gotshal & Manges LLP supports biotech, pharma, and medical device clients in protecting their assets, with strong work in IP advice and litigation. The firm is also active in corporate matters such as cross-border M&A, strategic alliances, and licensing and collaboration agreements. Additionally, the team handles a broad range of litigation cases, including product liability, securities, commercial disputes, and antitrust. The practice is headed by New York-based Charan Sandhu who focuses on IP and complex commercial and technical matters, including tech transactions. Jeffrey Osterman departed the team to Paul, Weiss, Rifkind, Wharton & Garrison LLP in March 2025.
Legal 500 redaktioneller Kommentar
- Profil
Kernmandanten
- CareDx
- Invitae
- Synthego
- Bio-Rad Laboratories
- Sanofi
- Bruker
- Parse Biosciences
- Pacific Biosciences
- Bluestar Genomics
- Elanco Animal Health
Highlight-Mandate
- Represented Synthego in a Federal Circuit appeal of a PTAB decision, successfully securing the invalidation of two competitor patents, including all 63 claims in those patents.
- Secured decisive wins for Elanco Animal Health in securities fraud class actions in Indiana state and federal courts concerning an alleged COVID-era “channel-stuffing” scheme, and secured a favorable settlement in a related SEC inquiry.
- Representing Bio-Rad Laboratories in connection with two patent lawsuits brought by ChromaCode in the Northern District of California, both relating to digital PCR multiplexing.
Anwält*innen
Führende Partner*innen
Die stärksten Partner*innen ihres Praxisbereichs, die eine führende Rolle in signifikanten Mandaten einnehmen und weitreichende Anerkennung unter Wettbewerbern und Mandanten genießen.
Partner*innen der nächsten Generation
Juniorpartner*innen, die im Markt von Mandanten und Wettbewerbern anerkannt werden und in einigen Mandaten eine Schlüsselrolle einnehmen.
Derek Walter
Praxisleitung
Charan Sandhu